FDA.reportPublic FDA data

Application 201967

Type
ANDA
Sponsor
GLENMARK GENERICS

Application Products#

Product, Drug, Ingredient table
ProductDrugIngredientFormStrengthReference drugReference standard
001RIZATRIPTAN BENZOATERIZATRIPTAN BENZOATETABLET;ORALEQ 5MG BASENoNo
002RIZATRIPTAN BENZOATERIZATRIPTAN BENZOATETABLET;ORALEQ 10MG BASENoNo

NDC Listings For This Application#

NDC, Name, Nonproprietary name table
NDCNameNonproprietary nameLabelerMarketing categoryStatus
50090-2069rizatriptan benzoaterizatriptan benzoateA-S Medication SolutionsANDACurrent
68462-465rizatriptan benzoaterizatriptan benzoateGlenmark Pharmaceuticals Inc., USAANDACurrent
68462-465rizatriptan benzoaterizatriptan benzoateGlenmark Pharmaceuticals Inc., USAANDACurrent
68462-465rizatriptan benzoaterizatriptan benzoateGlenmark Pharmaceuticals Inc., USAANDACurrent
68462-465rizatriptan benzoaterizatriptan benzoateGlenmark Pharmaceuticals Inc., USAANDACurrent
68462-465rizatriptan benzoaterizatriptan benzoateGlenmark Pharmaceuticals Inc., USAANDACurrent
68462-466rizatriptan benzoaterizatriptan benzoateGlenmark Pharmaceuticals Inc., USAANDACurrent
68462-466rizatriptan benzoaterizatriptan benzoateGlenmark Pharmaceuticals Inc., USAANDACurrent
68462-466rizatriptan benzoaterizatriptan benzoateGlenmark Pharmaceuticals Inc., USAANDACurrent
68462-466rizatriptan benzoaterizatriptan benzoateGlenmark Pharmaceuticals Inc., USAANDACurrent
68462-466rizatriptan benzoaterizatriptan benzoateGlenmark Pharmaceuticals Inc., USAANDACurrent